Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy

Abstract

Purpose The first-line chemotherapy treatment protocol for gastric cancer is combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP). The aim of this study was to engineer prodrug-based nanostructured lipid carriers (NLC) platform for codelivery of 5-FU and CDDP to enhance therapy and decrease toxicity. Methods First, 5-FU-stearic acid lipid conjugate was synthesized by two steps. Second, 5-FU-stearic acid prodrug and CDDP were loaded in NLC. Finally, hyaluronic acid (HA) was coated onto NLC surface. Average size, zeta potential, and drug loading capacity of NLC were evaluated. Human gastric cancer cell line BGC823 (BGC823 cells) was used for the testing of in vitro cytotoxicity assays. In vivo antitumor activity of NLC was evaluated in mice bearing BGC823 cells model. Results HA-coated 5-FU-stearic acid prodrug and CDDP-loaded NLC (HA-FU/C-NLC) showed a synergistic effect in combination therapy and displayed the greatest antitumor activity than all of the free drugs or uncoated NLC in vitro and in vivo. Conclusion This work reveals that HA-coated NLC could be used as a novel carrier to code-liver 5-FU and CDDP for gastric cancer therapy. HA-FU/C-NLC could be a promising targeted and combinational therapy in nanomedicine.

Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid–polymer hybrid nanoparticles

“…Evaluation of drug–drug interaction plays an important role in all areas of medicine and particularly in cancer chemotherapy where combination therapy is commonly used. 46 To determine the possible effect of the drug combination, mathematical model-based method has been introduced. LPNs combing the mechanical advantages of biodegradable polymers and liposomes are core-shell nanoparticles structures comprising polymer cores and lipid shells.…”

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

“…The pH value of the bloodstream is ~7.4, while the existing tumoral pH and that of endocytic compartments of the cells generally range from 4 to 6. 38 This difference in pH value makes pH-triggered drug release possible. The DOX release rate from LNPs increased when pH was lowered.…”

Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy

“…Evaluation of drug–drug interaction is important in all areas of medicine and particularly in combination cancer chemotherapy. 44 Chou and Talalay 45 in 1983 introduced the term CI for quantification of synergism or antagonism for two drugs. If the CI value is <1, synergism is indicated, and if the CI value is 1 to infinity, antagonism is indicated.…”